Vanguard Group Inc. Increases Stake in Maze Therapeutics, Inc. $MAZE

Vanguard Group Inc. grew its stake in Maze Therapeutics, Inc. (NASDAQ:MAZE) by 27.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,697,015 shares of the company’s stock after buying an additional 362,060 shares during the quarter. Vanguard Group Inc. owned 3.53% of Maze Therapeutics worth $70,307,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Woodline Partners LP boosted its stake in shares of Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after buying an additional 94,529 shares during the period. Marshall Wace LLP lifted its stake in Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after purchasing an additional 758,104 shares during the last quarter. ArrowMark Colorado Holdings LLC purchased a new stake in Maze Therapeutics during the third quarter worth approximately $14,135,000. Balyasny Asset Management L.P. purchased a new stake in Maze Therapeutics during the third quarter worth approximately $11,246,000. Finally, Boothbay Fund Management LLC lifted its stake in Maze Therapeutics by 365.9% during the third quarter. Boothbay Fund Management LLC now owns 351,875 shares of the company’s stock worth $9,124,000 after purchasing an additional 276,345 shares during the last quarter.

Insiders Place Their Bets

In other Maze Therapeutics news, CMO Harold Bernstein sold 30,000 shares of Maze Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $50.45, for a total transaction of $1,513,500.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Amy Bachrodt sold 2,500 shares of Maze Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total value of $73,600.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at approximately $381,689.60. This trade represents a 16.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 70,000 shares of company stock valued at $2,955,775 over the last quarter. Company insiders own 5.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MAZE shares. HC Wainwright boosted their target price on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Truist Financial decreased their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 14th. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. JPMorgan Chase & Co. boosted their target price on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Finally, Guggenheim boosted their target price on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Maze Therapeutics currently has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Trading Down 2.0%

MAZE opened at $26.43 on Friday. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -10.45 and a beta of 2.50. Maze Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $53.65. The business’s 50 day moving average is $33.83 and its two-hundred day moving average is $38.01. The company has a quick ratio of 15.50, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The business had revenue of $20.00 million during the quarter. On average, research analysts predict that Maze Therapeutics, Inc. will post -2.59 EPS for the current year.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.